Cisplatin Eligibility Issues and Alternative Regimens in Locoregionally Advanced Head and Neck Cancer: Recommendations for Clinical Practice

Well-designed randomized trials provide the highest level of scientific evidence to guide clinical decision making. In chemoradiotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN), data support the use of three cycles of 100 mg/m(2) cisplatin given every 3 weeks concurr...

Descripción completa

Detalles Bibliográficos
Autores principales: Szturz, Petr, Cristina, Valerie, Herrera Gómez, Ruth Gabriela, Bourhis, Jean, Simon, Christian, Vermorken, Jan B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6579895/
https://www.ncbi.nlm.nih.gov/pubmed/31245288
http://dx.doi.org/10.3389/fonc.2019.00464

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6579895/
https://www.ncbi.nlm.nih.gov/pubmed/31245288
http://dx.doi.org/10.3389/fonc.2019.00464

Ejemplares similares